Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Emtriva: New Formulation and Labeling Changes

September 28, 2005

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

On September 28, 2005, The Food and Drug Administration approved EMTRIVA (emtricitabine) Oral Solution 10 mg/mL. The approval of this Oral Solution formulation allows for dosing recommendations in pediatric patients. EMTRIVA is now indicated in combination with other antiretroviral agents, for the treatment of HIV-1 infection in patients over three months of age.

In addition the following changes to the label were made: (Please refer to the attached PDF document for specific details)


Clinical Pharmacology Section

Pharmacokinetic data in pediatrics, renal impairment information and results from a drug-drug interaction study with zidovudine were included.


Indications and Usage

The indication was expanded to include patients over three months of age.

Advertisement

Precautions

Addition of zidovudine to the drug interactions section, addition of the immune reconstitution syndrome section, updated carcinogenicity data and pediatric use statements were included.


Adverse Reactions

This section was updated to include data in pediatric patients.


Dosage and Administration

This section was revised to include dosing information in pediatric patients with the oral solution and capsule formulations. In addition, dosing information for the oral solution for adult patients was included. A new table was added to include dose adjustment information in adults with renal impairment for the capsule and oral solution formulations.


How Supplied

Data on storage conditions for the Oral Solution were included.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.
 
See Also
More Research on HIV/AIDS in Children
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement